Balda AG has acquired HK Plastics Engineering, Inc.
Balda AG (Balda) has acquired 100% of the shares of HK Plastics Engineering, Inc. for an undisclosed consideration.
HK Plastics Engineering, Inc., a family-owned business based in Oceanside, California is a full-service supplier of injection molded plastics and associated molds. It services a range from design and development to tool manufacturing and from the molding process up to mechanical installations. More than 80 percent of its revenue comes from medical customers, especially in the area of medical diagnostics.
Germany-based Balda develops and manufactures high quality plastic systems for medical appliances as well as complete electronic products for communication and entertainment. The Balda medical segment in Bad Oeynhausen develops and produces plastic solutions for the medical technology, pharmaceutical and diagnosis markets.
This acquisition is part of Balda’s buy-and-build strategy for its medical segment. Through this acquisition Balda extends its presence in the strategically important US market and particularly strengthens its medical business.
Oaklins' team in Germany advised Balda in this transaction.
Talk to the deal team
Related deals
MEDIK Hospital Design Group has been acquired by STERIS
The private shareholders of MEDIK Hospital Design Group have sold their shares to STERIS plc. Together, MEDIK and STERIS will expand their offerings for hospitals and ambulatory surgery centers worldwide. MEDIK’s solutions ideally complement STERIS’ existing portfolio, enabling the combined group to strengthen its position as a leading provider of turnkey room solutions in surgical and IPT environments. The MEDIK management team will actively support the next phase of growth.
Learn morebioXXmed AG has sold Rancoderm GmbH to Rose Investment- und Beteiligungs AG
Rancoderm GmbH has been acquired by Rose Investment- und Beteiligungs AG to secure the funding required for the final development and market approval of its medical device DermaPro. The acquisition will enable Rancoderm to bring DermaPro to market readiness and launch it as a certified medical product for broad distribution.
Learn moreBanook, backed by Motion Equity, has acquired Fluidda
Banook Group has acquired Fluidda NV, marking a strategic expansion into advanced in-silico trials and respiratory disease modeling. Combining Banook’s expertise in cardiac safety and clinical data services with Fluidda’s AI-driven respiratory analytics creates a powerful, integrated platform. This deal strengthens Banook’s position in the contract research organization (CRO) sector, offering pharmaceutical clients broader, technology-enabled solutions to drive drug development and reduce costs.
Learn more